Development of Novel Drugs to Accelerate Market Growth
Dermatological disorders are highly prevalent in various forms across the globe. According to the World Health Organization, more than 900 million people were affected by skin diseases in 2017. Out of these diseases, atopic dermatitis affects more than 300 million people globally. Around one-fifth of the victims include children. This increased incidence of this disease is expected to leverage the growth of the atopic dermatitis market in the foreseeable future.
Other factors, such as the development of novel pipeline drugs and rising demand for new biologics and product approvals, are also expected to augment atopic dermatitis drugs demand. The global atopic dermatitis market is project to show a stellar CAGR of 24.1% between 2020 and 2027, surpassing a valuation of US$ 19 Bn by the end of the forecast period.
Biologics Drugs and PDE4 Inhibitors Account for Major Chunk of Market Share
The biologics drug segment maintained its supremacy in the global atopic dermatitis market in 2018. The segment will continue to acquire greater market share during the forecast period. This is attributed to new product launches and increased adoption of biological drugs across several regions. Projections indicate that the biologics segment is poised to account for a staggering CAGR of 32.1% between 2020 and 2027, surpassing a valuation of US$ 15 Bn. This is followed by the growth of PDE4 Inhibitors, forecast to grow at a similar CAGR during the forecast period. Increased affordability of treatment, extensive research and development of PDE4 Inhibitors and high adoption in key markets are factors driving growth.
To get in-depth and incisive insights on the atopic dermatitis market, ask an analyst here
Retail Pharmacies to be Lucrative Revenue Pockets of Global Atopic Dermatitis Market
By end-use, retail pharmacies are expected to be the most lucrative. Anticipated market share is pegged at almost four-fifth of the global atopic dermatitis market. The growth of this segment is driven by increased number of retail pharmacy stores around the world and availability of small molecule drugs. Easy availability of therapeutic drugs at the desired location, affordability and convenience are some other factors boosting the growth of the market. Projected CAGR for retail pharmacies amounts for 27% during the forecast period.
Get an exhaustive overview of the atopic dermatitis market by requesting for a report sample here
North America to Enjoy Burgeoning Growth, Europe Closing In
North America is anticipated to maintain its regional supremacy throughout the forecast period. This is attributed to adoption of advanced products, adequate reimbursement coverage for pharmaceutical companies and greater market penetration of new players. The region is anticipated to grow at a dexterous CAGR of 27% during the forecast period, comprising more than half the total share of the atopic dermatitis market.
Trailing behind North America is Europe, comprising around one-third of the global atopic dermatitis market. Increased awareness about atopic dermatitis, favorable medical reimbursement policies and well-established healthcare facilities are projected to leverage Europe’s market share. Expected CAGR is pegged at a robust 25% for the forecast period.
Product Development to Remain Growth Lever for Market Players
The global atopic dermatitis drugs market is dominated by six key players. These are Mylan M.V, Pfizer, Inc., LEO Pharma A/S, Teva Pharmaceutical Industries Ltd, Sanofi and Novartis AG. Investment in research and development of new pharmaceutical drugs is the key strategy for market expansion of the aforementioned companies. For example, Sanofi Genzyme manufactures the Biologics drug DUPIXNET ® which cures skin lesions and reduces itching. It does so by inhibiting the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. These proteins are key contributors of type-2 inflammation which occurs in atopic dermatitis. On a similar plane, Pfizer Inc., manufactures Eucrisa (crisaborole) which consists of PDE4 Inhibitors to treat skin ailments, particularly Eczema. The ointment targets the enzyme Phosphodiesterase-4, or PDE4, by blocking the over reactive enzymes within skin cells to prevent inflammation.
Global Atopic Dermatitis Drugs Market- Scope of the Report
The recent study by Fact.MR on Global Atopic Dermatitis Drugs Market offers a 7-year forecast between 2020 and 2027. The study analyzes crucial trends that are currently determining the growth of global atopic dermatitis drugs market. This report explicates on vital dynamics such as the drivers, restraints and opportunities for key market players along with key stakeholders as well as emerging players associated with the manufacturing of bentonite. The study also provides dynamics that are responsible for influencing the future status of the global atopic dermatitis drugs market over the forecast period.
A detailed assessment of global atopic dermatitis drugs market value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in the report. A list of prominent companies operating in the global atopic dermatitis drugs market along with their product portfolio enhances the reliability of this comprehensive research study.
Global Atopic Dermatitis Drugs Market: Report Summary
The study offers a comprehensive analysis on diverse features including production capacities, demand, product developments, revenue generation and sales in global atopic dermatitis drugs market across the globe.
A comprehensive estimate on global atopic dermatitis drugs market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of global atopic dermatitis drugs market during the forecast period. Price point comparison by region with global average price is also considered in the study.
Global Atopic Dermatitis Drugs Market Segmentation
Fact.MR has studied the global atopic dermatitis drugs market with detailed segmentation on the basis product type, application and key regions.
|
Drug Class |
Distribution Channel |
Key Regions |
|
Corticosteroids |
Hospital Pharmacies |
North America |
|
PDE4 Inhibitors |
Retail Pharmacies |
Europe |
|
Biologics |
Online Pharmacies |
Asia Pacific |
|
Skin Barrier Emollients |
Latin America |
|
|
CNI Immunosuppressants |
Middle East & Africa |
|
|
Others |
||
“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”
Global Atopic Dermatitis Drugs Market: Analysis on Market Size Evaluation
Global atopic dermatitis drugs market has been analyzed for each market segment, in terms of value (US$ Mn).
Market estimates at global and regional levels for atopic dermatitis drugs is available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent Global Atopic Dermatitis Drugs Market segments, along with market attractiveness evaluation has been incorporated in the report.
Global Atopic Dermatitis Drugs Market: Inspected Assessment on Regional Segments
Key sections have been elaborated in the atopic dermatitis drugs report, which have helped to deliver projection on the regional markets. These chapters include the regional macros (economic and business environment outlook), which are expected to have a momentous influence on the growth of global atopic dermatitis drugs market during the forecast period.
Country-specific valuation on demand for atopic dermatitis drugs has been offered for each regional market, along with the market scope estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.
Detailed breakup in terms of value for emerging countries has also been included in the report.
Global Atopic Dermatitis Drugs Market: In-Depth Analysis on Competitive Landscape
The report sheds light on the leading manufacturers of asthma spacers along with their detailed profiles. Essential and up-to-date data information related to the market performers, who are principally engaged in the production of asthma spacers, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which includes essentials such as product portfolio, key strategies along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through the matrix for all the prominent players thus providing the readers with actionable insights, which helps in thoughtfully presenting market status, and predicting the competition level in global atopic dermatitis drugs market. Prominent manufacturers with established market presence in global atopic dermatitis drugs market are Mylan N.V, Pfizer, Inc., LEO Pharma A/S, Teva Pharmaceutical Industries Ltd, Sanofi and Novartis AG.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Atopic Dermatitis Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, 2020–2027
5. Market Outlook
5.1. Disease Epidemiology
5.2. Pipeline Analysis
5.3. Recent Development
6. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, by Drug Class
6.1. Introduction & Definition
6.2. Market Value Forecast by Drug Class, 2020–2027
6.2.1. Corticosteroids
6.2.2. PDE4 Inhibitors
6.2.3. Biologics
6.2.4. Skin Barrier Emollients
6.2.5. CNI Immunosuppressants
6.2.6. Others
6.3. Market Attractiveness by Drug Class
7. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, by Distribution Channel
7.1. Introduction & Definition
7.2. Market Value Forecast by Distribution Channel, 2020–2027
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
7.3. Market Attractiveness by Distribution Channel
8. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Market Value Forecast by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness by Country/Region
9. North America Atopic Dermatitis Drugs Market Analysis and Forecast
9.1. Introduction
9.2. Market Value Forecast by Drug Class, 2020–2027
9.2.1. Corticosteroids
9.2.2. PDE4 Inhibitors
9.2.3. Biologics
9.2.4. Skin Barrier Emollients
9.2.5. CNI Immunosuppressants
9.2.6. Others
9.3. Market Value Forecast by Distribution Channel, 2020–2027
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Value Forecast by Country, 2020–2027
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Atopic Dermatitis Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Market Value Forecast by Drug Class, 2020–2027
10.2.1. Corticosteroids
10.2.2. PDE4 Inhibitors
10.2.3. Biologics
10.2.4. Skin Barrier Emollients
10.2.5. CNI Immunosuppressants
10.2.6. Others
10.3. Market Value Forecast by Distribution Channel, 2020–2027
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Value Forecast by Country/Sub-region, 2020–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Atopic Dermatitis Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Market Value Forecast by Drug Class, 2020–2027
11.2.1. Corticosteroids
11.2.2. PDE4 Inhibitors
11.2.3. Biologics
11.2.4. Skin Barrier Emollients
11.2.5. CNI Immunosuppressants
11.2.6. Others
11.3. Market Value Forecast by Distribution Channel, 2020–2027
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Value Forecast by Country/Sub-region, 2020–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Atopic Dermatitis Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Market Value Forecast by Drug Class, 2020–2027
12.2.1. Corticosteroids
12.2.2. PDE4 Inhibitors
12.2.3. Biologics
12.2.4. Skin Barrier Emollients
12.2.5. CNI Immunosuppressants
12.2.6. Others
12.3. Market Value Forecast by Distribution Channel, 2020–2027
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Market Value Forecast by Country/Sub-region, 2020–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Atopic Dermatitis Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Market Value Forecast by Drug Class, 2020–2027
13.2.1. Corticosteroids
13.2.2. PDE4 Inhibitors
13.2.3. Biologics
13.2.4. Skin Barrier Emollients
13.2.5. CNI Immunosuppressants
13.2.6. Others
13.3. Market Value Forecast by Distribution Channel, 2020–2027
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Market Value Forecast by Country/Sub-region, 2020–2027
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competitive Landscape
14.1. Company Profiles
14.1.1. Mylan N.V.
14.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.1.2. Product Portfolio
14.1.1.3. SWOT Analysis
14.1.1.4. Strategic Overview
14.1.1.5. Financial Overview
14.1.2. Pfizer, Inc.
14.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.2.2. Product Portfolio
14.1.2.3. SWOT Analysis
14.1.2.4. Strategic Overview
14.1.2.5. Financial Overview
14.1.3. LEO Pharma A/S
14.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.3.2. Product Portfolio
14.1.3.3. SWOT Analysis
14.1.3.4. Strategic Overview
14.1.3.5. Financial Overview
14.1.4. Teva Pharmaceutical Industries Ltd
14.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.4.2. Product Portfolio
14.1.4.3. SWOT Analysis
14.1.4.4. Strategic Overview
14.1.4.5. Financial Overview
14.1.5. Sanofi
14.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.5.2. Product Portfolio
14.1.5.3. SWOT Analysis
14.1.5.4. Strategic Overview
14.1.5.5. Financial Overview
14.1.6. Novartis AG
14.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.6.2. Product Portfolio
14.1.6.3. SWOT Analysis
14.1.6.4. Strategic Overview
14.1.6.5. Financial Overview
Fact.MR offers custom research services that help clients to get specific research solutions
Related reports
We are committed towards customer satisfaction and quality service.
Our Clients
Atopic Dermatitis Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2027